Key result
Intravenous ketorolac 60 mg did not inhibit platelet function by bleeding time, aggregometry, or TEG during general anesthesia, despite near complete abolition of TxB2 production (P=0.002).
Why the study?
Does intravenous ketorolac worsen platelet function in ASA physical status I patients undergoing knee arthroscopy under general anesthesia?
Population
30 ASA physical status I patients undergoing general anesthesia for knee arthroscopy
Comparison
Ketorolac 60 mg IV administered 15 min after… vs Placebo IV
Design
RCT, randomized
Follow-up
45 min after administration of study drug
Authors
Loading...
Supports ketorolac use without platelet-related hemostatic concern in this setting; extends evidence that TxB2 suppression need not impair functional assays under anesthesia.
RCT (n=30)
randomized
Does intravenous ketorolac worsen platelet function in ASA physical status I patients undergoing knee arthroscopy under general anesthesia?
p-value: p=0.002
A single intraoperative dose of intravenous ketorolac does not inhibit platelet function during knee arthroscopy under general anesthesia, despite abolishing thromboxane B2 production.
Thwaites et al. (1995) conducted an RCT in Knee arthroscopy under general anesthesia (n=30). Ketorolac Tromethamine vs. Placebo IV was evaluated on Platelet function changes (bleeding time, platelet aggregometry, thromboclastography, and serum thromboxane B2 assays) (p=0.002). Intravenous ketorolac 60 mg did not inhibit platelet function by bleeding time, aggregometry, or TEG during general anesthesia, despite near complete abolition of TxB2 production (P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: